A new vaccine targeting RANKL, prepared by incorporation of an unnatural Amino acid into RANKL, prevents OVX-induced bone loss in mice

Feng Li, Huan Li, Qian Zhai, Fuyang Li, Tailin Wu, Xin Sha, Bobo Zhang, Weizhou Yang, Zifan Lu, Huiren Tao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bone homeostasis is maintained by a dynamic balance between osteoblastic bone formation and osteoclastic bone resorption. The receptor activator of nuclear-κB ligand (RANKL) is essential for the function of the bone-resorbing osteoclasts, and targeting RANKL has been proved highly successful in osteoporosis patients. This study aimed to design a novel vaccine targeting RANKL and evaluate its therapeutic effects in OVX-induced bone loss model. Anti-RANKL vaccine was generated by incorporating the unnatural amino acid p-nitrophenylalanine (pNO2Phe) into selected sites in the murine RANKL (mRANKL) molecule. Specifically, mutation of a single tyrosine residue Tyr234 (Y234) or Tyr240 (Y240) of mRANKL to pNO2Phe (thereafter named as Y234pNO2Phe or Y240pNO2Phe) induced a high titer antibody response in mice, whereas no significant antibody response was observed for the wild type mRANKL (WT mRANKL). The antiserum induced by Y234pNO2Phe or Y240pNO2Phe could efficiently prevent osteoclastogenesis in vitro. Moreover, immunization with Y234pNO2Phe or Y240pNO2Phe could also prevent OVX-induced bone loss in mice, suggesting that selected pNO2Phe-substituted mRANKL may pave the way for creating a novel vaccine to treat osteoporosis.

Original languageEnglish (US)
Pages (from-to)648-654
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume499
Issue number3
DOIs
StatePublished - May 15 2018

Fingerprint

Bone
Vaccines
Amino Acids
Bone and Bones
Osteogenesis
Osteoporosis
Antibody Formation
Therapeutic Uses
Osteoclasts
Bone Resorption
Cytoplasmic and Nuclear Receptors
Immunization
Tyrosine
Immune Sera
Homeostasis
Antibodies
Ligands
Mutation
Molecules

Keywords

  • Osteoclast
  • Osteoporosis
  • RANKL
  • Unnatural amino acid
  • Vaccine

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

A new vaccine targeting RANKL, prepared by incorporation of an unnatural Amino acid into RANKL, prevents OVX-induced bone loss in mice. / Li, Feng; Li, Huan; Zhai, Qian; Li, Fuyang; Wu, Tailin; Sha, Xin; Zhang, Bobo; Yang, Weizhou; Lu, Zifan; Tao, Huiren.

In: Biochemical and Biophysical Research Communications, Vol. 499, No. 3, 15.05.2018, p. 648-654.

Research output: Contribution to journalArticle

Li, Feng ; Li, Huan ; Zhai, Qian ; Li, Fuyang ; Wu, Tailin ; Sha, Xin ; Zhang, Bobo ; Yang, Weizhou ; Lu, Zifan ; Tao, Huiren. / A new vaccine targeting RANKL, prepared by incorporation of an unnatural Amino acid into RANKL, prevents OVX-induced bone loss in mice. In: Biochemical and Biophysical Research Communications. 2018 ; Vol. 499, No. 3. pp. 648-654.
@article{0cbd147e4092439ba63d71534394903d,
title = "A new vaccine targeting RANKL, prepared by incorporation of an unnatural Amino acid into RANKL, prevents OVX-induced bone loss in mice",
abstract = "Bone homeostasis is maintained by a dynamic balance between osteoblastic bone formation and osteoclastic bone resorption. The receptor activator of nuclear-κB ligand (RANKL) is essential for the function of the bone-resorbing osteoclasts, and targeting RANKL has been proved highly successful in osteoporosis patients. This study aimed to design a novel vaccine targeting RANKL and evaluate its therapeutic effects in OVX-induced bone loss model. Anti-RANKL vaccine was generated by incorporating the unnatural amino acid p-nitrophenylalanine (pNO2Phe) into selected sites in the murine RANKL (mRANKL) molecule. Specifically, mutation of a single tyrosine residue Tyr234 (Y234) or Tyr240 (Y240) of mRANKL to pNO2Phe (thereafter named as Y234pNO2Phe or Y240pNO2Phe) induced a high titer antibody response in mice, whereas no significant antibody response was observed for the wild type mRANKL (WT mRANKL). The antiserum induced by Y234pNO2Phe or Y240pNO2Phe could efficiently prevent osteoclastogenesis in vitro. Moreover, immunization with Y234pNO2Phe or Y240pNO2Phe could also prevent OVX-induced bone loss in mice, suggesting that selected pNO2Phe-substituted mRANKL may pave the way for creating a novel vaccine to treat osteoporosis.",
keywords = "Osteoclast, Osteoporosis, RANKL, Unnatural amino acid, Vaccine",
author = "Feng Li and Huan Li and Qian Zhai and Fuyang Li and Tailin Wu and Xin Sha and Bobo Zhang and Weizhou Yang and Zifan Lu and Huiren Tao",
year = "2018",
month = "5",
day = "15",
doi = "10.1016/j.bbrc.2018.03.205",
language = "English (US)",
volume = "499",
pages = "648--654",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A new vaccine targeting RANKL, prepared by incorporation of an unnatural Amino acid into RANKL, prevents OVX-induced bone loss in mice

AU - Li, Feng

AU - Li, Huan

AU - Zhai, Qian

AU - Li, Fuyang

AU - Wu, Tailin

AU - Sha, Xin

AU - Zhang, Bobo

AU - Yang, Weizhou

AU - Lu, Zifan

AU - Tao, Huiren

PY - 2018/5/15

Y1 - 2018/5/15

N2 - Bone homeostasis is maintained by a dynamic balance between osteoblastic bone formation and osteoclastic bone resorption. The receptor activator of nuclear-κB ligand (RANKL) is essential for the function of the bone-resorbing osteoclasts, and targeting RANKL has been proved highly successful in osteoporosis patients. This study aimed to design a novel vaccine targeting RANKL and evaluate its therapeutic effects in OVX-induced bone loss model. Anti-RANKL vaccine was generated by incorporating the unnatural amino acid p-nitrophenylalanine (pNO2Phe) into selected sites in the murine RANKL (mRANKL) molecule. Specifically, mutation of a single tyrosine residue Tyr234 (Y234) or Tyr240 (Y240) of mRANKL to pNO2Phe (thereafter named as Y234pNO2Phe or Y240pNO2Phe) induced a high titer antibody response in mice, whereas no significant antibody response was observed for the wild type mRANKL (WT mRANKL). The antiserum induced by Y234pNO2Phe or Y240pNO2Phe could efficiently prevent osteoclastogenesis in vitro. Moreover, immunization with Y234pNO2Phe or Y240pNO2Phe could also prevent OVX-induced bone loss in mice, suggesting that selected pNO2Phe-substituted mRANKL may pave the way for creating a novel vaccine to treat osteoporosis.

AB - Bone homeostasis is maintained by a dynamic balance between osteoblastic bone formation and osteoclastic bone resorption. The receptor activator of nuclear-κB ligand (RANKL) is essential for the function of the bone-resorbing osteoclasts, and targeting RANKL has been proved highly successful in osteoporosis patients. This study aimed to design a novel vaccine targeting RANKL and evaluate its therapeutic effects in OVX-induced bone loss model. Anti-RANKL vaccine was generated by incorporating the unnatural amino acid p-nitrophenylalanine (pNO2Phe) into selected sites in the murine RANKL (mRANKL) molecule. Specifically, mutation of a single tyrosine residue Tyr234 (Y234) or Tyr240 (Y240) of mRANKL to pNO2Phe (thereafter named as Y234pNO2Phe or Y240pNO2Phe) induced a high titer antibody response in mice, whereas no significant antibody response was observed for the wild type mRANKL (WT mRANKL). The antiserum induced by Y234pNO2Phe or Y240pNO2Phe could efficiently prevent osteoclastogenesis in vitro. Moreover, immunization with Y234pNO2Phe or Y240pNO2Phe could also prevent OVX-induced bone loss in mice, suggesting that selected pNO2Phe-substituted mRANKL may pave the way for creating a novel vaccine to treat osteoporosis.

KW - Osteoclast

KW - Osteoporosis

KW - RANKL

KW - Unnatural amino acid

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85044602394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044602394&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2018.03.205

DO - 10.1016/j.bbrc.2018.03.205

M3 - Article

AN - SCOPUS:85044602394

VL - 499

SP - 648

EP - 654

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -